Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NCT05935358)

🧪 Interventions in This Study

• Nuwiq (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Severe haemophilia A (FVIII activity \[FVIII:C\] \<1%) according to medical history
2. Male patients at least 12 years of age
3. Previous treatment with any FVIII product(s) for at least 150 exposure days
4. On regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring FVIII treatment
5. Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (18 Sites)

• UT Southwestern Medical Center — Dallas, Texas
• University Hospital Centre Zagreb — Zagreb,
• Helsinki University Hospital — Helsinki,
• CHU de Nantes Hôtel-Dieu — Nantes,
• CHRU de Tours — Tours,
• Vivantes Klinikum im Friedrichshein (KFH) — Berlin,
• Gerinnungszentrum Rhein-Ruhr — Duisburg,
• Universitätsklinikum Hamburg Eppendorf (UKE) — Hamburg,
• Christian Medical College Vellore — Vellore, Tamil Nadu
• St. John's Medical College Hospital — Bengaluru,
• Azienda Ospedaliera Pugliese Ciaccio — Catanzaro,
• Azienda Ospedaliero Universitaria Careggi - Centro Emofilia — Florence,
• Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital — Milan,
• Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia — Skopje,
• Clinical Center for Serbia Belgrade — Belgrade,
• Hospital Universitario La Paz — Madrid,
• Hospital Universitario Virgen del Rocio — Seville,
• St. James's University Hospital — Leeds,

📞 Contact the Study Coordinator

Phone: +41 554512141

Email: Sigurd.Knaub@octapharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Severe Hemophilia A

• A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis — Los Angeles, California
• A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. — Los Angeles, California
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors — Phoenix, Arizona

Explore by condition: All Severe Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.